These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25742236)

  • 21. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choline PET/CT for imaging prostate cancer: an update.
    Kitajima K; Murphy RC; Nathan MA
    Ann Nucl Med; 2013 Aug; 27(7):581-91. PubMed ID: 23632880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early ¹⁸F-FCH PET/CT?
    Di Biagio D; Chiaravalloti A; Tavolozza M; Abbatiello P; Schillaci O
    Ann Nucl Med; 2015 Dec; 29(10):861-9. PubMed ID: 26261000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.
    Igerc I; Kohlfürst S; Gallowitsch HJ; Matschnig S; Kresnik E; Gomez-Segovia I; Lind P
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):976-83. PubMed ID: 18188560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standardization of acquisition protocols using PET/CT with
    Garcia JR; Cozar M; Soler M; Bassa P; Riera E; Buxeda M; Valls E; Ferrer J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):204-211. PubMed ID: 32192907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
    Steiner Ch; Vees H; Zaidi H; Wissmeyer M; Berrebi O; Kossovsky MP; Khan HG; Miralbell R; Ratib O; Buchegger F
    Nuklearmedizin; 2009; 48(1):1-9; quiz N2-3. PubMed ID: 19212605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.
    von Eyben FE; Kairemo K
    Nucl Med Commun; 2014 Mar; 35(3):221-30. PubMed ID: 24240194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
    Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
    Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.
    Breeuwsma AJ; Pruim J; van den Bergh AC; Leliveld AM; Nijman RJ; Dierckx RA; de Jong IJ
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):160-4. PubMed ID: 19783375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
    Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
    Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
    Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography.
    Kwee SA; Coel MN; Lim J; Ko JP
    J Urol; 2005 Jan; 173(1):252-5. PubMed ID: 15592091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.
    Shiiba M; Ishihara K; Kimura G; Kuwako T; Yoshihara H; Sato H; Kondo Y; Tsuchiya S; Kumita S
    Ann Nucl Med; 2012 Feb; 26(2):138-45. PubMed ID: 22069194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.